N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 ClinicalTrials.gov

A Phase 1 Trial of GEN1119 in Participants With Solid Tumors

Sponsor: Genmab • ClinicalTrials.gov ID: NCT07695831

Registry updated: 2026-10-06
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The purpose of this trial is to learn about the safety and efficacy of GEN1119 when it is used for the treatment of participants with certain types of cancer. The trial has multiple parts. The first part of the trial will test different doses of GEN1119 to find out if it is safe and to determine what are the best doses to use. The second part will further refine this optimal dose. The third part continues to test the safety and how well GEN1119 works in additional participants with specific cancer types and at doses chosen based on the results of the first 2 parts of the trial. For each participant, the trial will last approximately 18 months but this may vary for each individual. This includes a Screening Period of up to 21 days before receiving trial treatment, an estimated 5 months of treatment (the duration of treatment may vary for each participant), and approximately 12.5 months of follow up after trial treatment ends (the duration of follow up may vary for each participant). Participation in the trial will require visits to the site, with more frequent visits during the first 6 weeks of treatment and then less frequent visits afterwards. At site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, computed tomography \[CT\] scans) to monitor whether the treatment is safe and effective. All participants will receive active drug; no one will be given placebo.

Interventions

  • GEN1119 (Drug)
    Administered at certain DLs on specified days.

Eligibility criteria

Key Inclusion Criteria: * Have histologically or cytologically confirmed diagnosis of protocol-specified solid tumours. * Have progressed on standard of care (SoC) therapy applicable for the tumor type, or for whom there is no available SoC therapy likely to provide clinical benefit, and for whom experimental therapy with GEN1119 may be a suitable option in the opinion of the investigator. * Have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. * Have acceptable laboratory test results before GEN1119 administration per protocol Key Exclusion Criteria: * Prior treatment with certain protocol-defined therapy. * Prior treatment with T-cell engagers, chimeric antigen receptor T-cell (CAR-T-cell) therapies, other protocol defined therapies, or other therapeutic moieties targeting certain protocol-defined molecules. * Treatment with an anticancer agent within 4 weeks or within 5 half lives of the drug, whichever is shorter, but not within 2 weeks before Cycle 1 Day 1 (C1D1). * Has clinically significant toxicities from previous anticancer therapies that have not resolved to baseline levels or to Grade 1 or lower, except for anorexia, hyperthyroidism, hypothyroidism, and peripheral neuropathy, which must have recovered to ≤ Grade 2. There is no limitation for alopecia from previous therapies. * Participant should not have active Hepatitis B infection. Participants with prior infections or chronic infections are allowed if monitored or treated as per local SOC and are negative for hepatitis B virus (HBV) DNA measured viral load. * Hepatitis C virus (HCV): Known active HCV infection (defined as positive for HCV ribonucleic acid \[RNA\] \[qualitative\]). Note: Other protocol-defined Inclusion and Exclusion criteria may apply.

Conditions

Solid Tumours

Locations

  • Centre Eugene Marquis — Rennes, Ille Et Vilaine, France
  • Kansai Medical University Hospital — Hirakata, Osaka, Japan
  • National Cancer Center Hospital — Chuo Ku, Tokyo, Japan
  • The Cancer Institute Hospital Of JFCR — Koto-Ku, Tokyo, Japan
  • START - Hospital HM Nou Delfos — Barcelona, Catalonia, Spain
  • START Rioja - Hospital Universitario San Pedro — Logroño, La Rioja, Spain
  • START Madrid - Hospital Universitario Fundacion Jimenez Díaz — Madrid, Spain
  • START Madrid- CIOCC. Hospital HM Sanchinarro — Madrid, Spain
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record